Overview / Abstract: |
STATEMENT OF NEED T-cell lymphoma (TCL) is an uncommon subtype accounting for approximately 15% of all cases of non-Hodgkin lymphoma in the United States (LRF, 2022). Compared with its B-cell counterpart, TCL has a poor prognosis and is associated with a 5-year survival rate of less than 20%. The clinical and pathologic presentations of TCL are varied and often nonspecific, making diagnosis and treatment challenging (Salem et al, 2021). In this webinar, Aaron Goodman, MD, will update clinicians on evidence-based criteria for differential diagnosis, appraise efficacy and safety data to guide therapeutic selection for newly diagnosed and relapsed/refractory disease, and highlight strategies for optimizing treatment tolerability and improving outcomes in patients with TCL. TARGET AUDIENCE Hematology/oncology physicians, nurse practitioners, physician assistants, oncology nurses, and other health care professionals involved in the treatment of patients with T-cell lymphoma (TCL). LEARNING OBJECTIVES Upon completion of this activity, participants should be able to: - Assess guideline recommendations for the diagnostic workup of TCL |
Expiration |
Jun 29, 2023 |
Discipline(s) |
Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME |
Format |
Online, Webinar / Webcast / Video |
Credits / Hours |
1.25 |
Accreditation |
ANCC |
Presenters / Authors / Faculty |
Aaron Goodman, MD, UC San Diego Health |
Keywords / Search Terms |
Oncology, i3 Health, CME, NCPD, free CNE, free NCPD, Free CE, Free CME, Nursing, Oncology Nursing, Physician, T-cell, Lymphoma, T-cell lymphoma, Oncologist |